Editorial: CreakyJoints Urges Uninterrupted Supply of Biosimilars

The existence of CT-P13, a biosimilar version of infliximab (Remsima), and its recommended approval on Tuesday by the FDA Arthritis Advisory Committee, is reason to celebrate.

While this vote, and presumed FDA approval, will likely benefit patients, our optimism is tempered by not being able to predict if health insurance companies will return the savings to the patient community. CreakyJoints testified at the meeting saying:  “For us patients, biosimilars represent … expanded treatment options through a broader formulary, (but) we fear being switched from a drug that works to one we don’t know, without participating in the promised cost reductions.”